7 research outputs found
Genotoxicity produced by exposure to nanomaterials in the industrial field
No full textRESUMEN :
El desarrollo y crecimiento de la nanotecnología en las últimas décadas ha
permitido implementar numerosas ventajas en diversos productos de consumo,
tanto de uso cotidiano como profesional, gracias a la adición de NMs. A día de hoy,
los NMs más empleados en el ámbito industrial son la plata, el carbono y el titanio,
ampliamente utilizados en sectores como el textil, el automovilístico, el
agroalimentario, en la construcción, productos biomédicos, cosméticos, etc.
En el sector textil, los trabajadores de esta industria se encuentran
constantemente expuestos a NPs para poder crear lo que llamamos “nanotextiles”.
Estos nuevos textiles permitirán que los tejidos creados tengan mejores
propiedades mecánicas, eléctricas, ópticas y térmicas, químicas y de autonomía,
pero estas ventajas traerán consigo una gran consecuencia: la genotoxicidad.
En esta revisión bibliográfica queremos dar a conocer los posibles efectos
genotóxicos que puede dar la exposición a NMs dentro del ámbito industrial;
profundizando en la industria textil en las principales vías de exposición e
internalización, la toxicidad humana (centrándonos en la producción de ROS), las
diferentes fases de producción en las que existen riesgos de exposición (creación
de los NMs e incorporación a los textiles) y medidas preventivas y legislativas.ABSTRACT :
The development and growth of nanotechnology in recent decades has made
it possible to implement numerous advantages in various consumer products, both
for everyday and professional use, thanks to the addition of NMs. Today, the most
commonly used NMs in the industrial field are silver, carbon and titanium, which are
widely used in sectors such as textiles, the automotive industry, agri-food,
construction, biomedical products, cosmetics, etc.
In the textile sector, workers in this industry are constantly exposed to NPs in
order to create what we call "nanotextiles". These new textiles will allow the fabrics
created to have better mechanical, electrical, optical and thermal, chemical and
autonomy properties, but these advantages will bring with them a major
consequence: genotoxicity.
In this bibliographic review, we want to raise awareness of the possible
genotoxic effects of exposure to NMs in the industry field; deepening in the textile
industry in the main routes of exposure and internalisation, human toxicity (focusing
on the production of ROS), the different phases of production in which there are risks
of exposure (creation of NMs and incorporation into textiles) and preventive and
legislative measures.Grado en Medicin
Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor.
No full textEfficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study
No full text
Management of acquired hemophilia a: results from the spanish registry.
No full text[eng] The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed for a median of 12 months. Patients were predominantly male (56.3%), with median age at diagnosis of 74 years. AHA was more frequently idiopathic (44.1%) and autoimmune disorder-associated (31.7%). Thirty-four percent of patients were on antithrombotic therapy at diagnosis. Hemostatic treatment was used in 70% of patients. Recombinant activated factor VII was more frequently infused (60.3% vs 20.6% activated prothrombin complex concentrate). Only 1 patient did not achieve control of hemorrhage. Complete remission (CR) was achieved by 84.2% of cases after immunosuppressive therapy. Steroids alone were less efficient than the other strategies (68.2% vs 87.2%, P = .049), whereas no differences existed among these (steroids/cyclophosphamide, 88.5%, vs steroids/calcineurin inhibitors, 81.2%, vs rituximab-based regimens, 87.5%). Female sex and high inhibitor levels influenced CR negatively. Thirty-six deaths (23.8%) were reported. Main causes of death were infection (15 patients, 9.9%) and hemorrhage (5 patients, 3.3%). All hemorrhage-related and half the infection-related deaths occurred within 2 months of diagnosis. Prior antithrombotic therapy was inversely associated with survival, irrespective of age. Median age of nonsurvivors was significantly higher (79 vs 73 years in survivors). Patients dying of infection were older than the other nonsurvivors (85 vs 78 years). In summary, fatal infection in the first months is common in our series. Antithrombotic therapy is associated with mortality. Particular care should be taken to avoid misdiagnosis
Management of acquired hemophilia A: results from the Spanish registry
No full textThe Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed for a median of 12 months. Patients were predominantly male (56.3%), with median age at diagnosis of 74 years. AHA was more frequently idiopathic (44.1%) and autoimmune disorder-associated (31.7%). Thirty-four percent of patients were on antithrombotic therapy at diagnosis. Hemostatic treatment was used in 70% of patients. Recombinant activated factor VII was more frequently infused (60.3% vs 20.6% activated prothrombin complex concentrate). Only 1 patient did not achieve control of hemorrhage. Complete remission (CR) was achieved by 84.2% of cases after immunosuppressive therapy. Steroids alone were less efficient than the other strategies (68.2% vs 87.2%, P = .049), whereas no differences existed among these (steroids/cyclophosphamide, 88.5%, vs steroids/calcineurin inhibitors, 81.2%, vs rituximab-based regimens, 87.5%). Female sex and high inhibitor levels influenced CR negatively. Thirty-six deaths (23.8%) were reported. Main causes of death were infection (15 patients, 9.9%) and hemorrhage (5 patients, 3.3%). All hemorrhage-related and half the infection-related deaths occurred within 2 months of diagnosis. Prior antithrombotic therapy was inversely associated with survival, irrespective of age. Median age of nonsurvivors was significantly higher (79 vs 73 years in survivors). Patients dying of infection were older than the other nonsurvivors (85 vs 78 years). In summary, fatal infection in the first months is common in our series. Antithrombotic therapy is associated with mortality. Particular care should be taken to avoid misdiagnosis
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
No full textMortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis
